1. Libby P., Bonow R. O., Mann D. L. et al. Braunwald’s Heart Disease (8th ed.). Elsevier, 2008. 2274 p.

2. Malpas S. C.. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev, 2010; 90:513–57.

3. Fischer J. P., Young C. N., Fadel P. J. Central Sympathetic Overactivity: maladies and mechanisms. Auton Neurosci, 2009; 148:5–15.

4. Barretto A. C., Santos A. C., Munhoz R. et al. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol, 2008; 2:37–42.

5. Chan S. H., Chan J. Y. Brain stem NOS and ROS in neural mechanisms of hypertension. Antioxid Redox Signal, 2013; Feb 18.

6. Brinkmann J., Heusser K., Schmidt B. M. et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension, 2012; 60:1485–90.

7. Schailach M., Hering D., Lambert G. et al. Blood pressure and sympathetic nervous system response to renal denervation. Hypertension, 2013; 61: e13.

8. Jordan J., Mann J. F., Luft F. C. Research needs in the area of device-related treatments for hypertension. Kidney Int, 2013; Feb 27.

9. Pancheva A. V., Panchev V. S., Pancheva M. V. Functional sympatholysis in the present concept does not exist: arteriovenous pumping, supplied by capillary pumps, explains immediate exercise hyperemia. J Appl Physiol, 2013;114:428.

10. Jendzjowsky K. G. Short-term exercise training enhances functional sympatholysis through a nitric oxide-dependent mechanism. J Physiol, 2013; Feb 25.

11. Daskalopoulous E. P., Malliou F., Rentesi G. et al. Stress is a critical player in CYP3A, CYP2C and CYP2D regulation: role of adrenergic receptor signalling pathways. Am J Physiol End Metab, 2012; 303: E40–54.

12. Casey D. P., Padilla J., Joyner M. J. et al. Alpha-adrenergic vasoconstriction contributes to the age-related increase in conduit artery retrograde and oscillatory shear. Hypertension, 2012; 60 (4):1016–22.

13. Ambavaram V. B., Nandigam V., Vemula M. et al. Liquid chromatography-tandem mass spectrometry method for simultaneous quandification of urapidil and aripiprazole in human plasma and its application to human pharmacokinetic study. Biomed Chromatogr, 2013; Mar 6.

14. Tomulic K., Pavicic S. J., Kocman B. et al. Successful management of unsuspected retroperitoneal paraganglioma via the use of combined epidural and general anesthesia: a case report. J Med Case Rep, 2013;7 (1):58.

15. Habbe N., Ruger F., Bojunga J. et al. Urapidil in the perioperative treatment of pheochromocytomas: a safe and cost-effective method. World J Surgery, 2013; Feb 5.

16. Minushkina L. O. Features of urapidil in treatment of resistant hypertension. Kardiologija, 2012; 52:77–82.

17. Semenova R. I., Musina N. S. Experience with ebrantil used in patients with resistant hypertension in chronic kidney disease. Ter Arkh, 2012; 84:72–4.

18. Carles G., Helou J., Dallah F. et al. Use of injectable urapidil in pregnancy-induced hypertension and preeclampsia. J Gynecol Obstetr Biol Reprod, 2012; 41:645–9.

19. Vuylsteke A., Vincent J. L., de La Garanderie DP et al. Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for Studying the Treatment of Acute hyperTension (Euro-STAT). Crit Care, 2011; 15: R271.

20. Gregorini L., Marco J., Heusch G. Peri-interventional coronary vasomotion. J Mol Cell Cardiology, 2012; 52:883–9.

21. Wang Z., Wang D. F., Lou N. Efficacy of sublingual nifedipine and intravenous uradipil for treatment of acute postoperative hypertension. Nan Fang Yi Ke Da Xue Xue Bao, 2011; 31:317–9.

22. Nirogi R., Kandikere V., Komarneni P. et al. Quantification of urapidil, a-1- adrenoreceptor antagonist, in plasma by LC–MS/MS: validation and application to pharmakokinetic studies. Biomed Chromatogr, 2011; 25:1319–26.

23. Ribas N. B., Perez J. E., Amoros CSM et al. Physical compatibility of sodium bicarbonate with other drugs often administered in the intensive care unit. Enferm Intensiva, 2011; 22 (2):78–82.

24. Buch J. Urapidil, a dual-acting antihypertensive agent: current usage considerarions. Adv Ther, 2010;27 (7):426–43.

25. He H., Li H., Tang X. Preparation of pH-dependent moified-release pellets of uradipil to improve its bioavailability. Pharm Dev Technol, 2011; 16:212–8.

26. Panossian L., Daley J. Sleep-disordered breathing. Continuum, 2013;19:86–103.

27. Chen J. L., Fu X. H., Jiang Y. F. et al. Effect of urapidil on heart function and ventricular systolic synchrony in acute myocardial infarction patients with no-reflow phenomenon after percutaneous intervention. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2008;20:197–9.

28. Yao D. K., Jia S. Q., Wang L. et al. Therapeutic effect of urapidil on myocardial perfusion in patients with ST-elevation acute coronary syndrome. Eur J Intern Med, 2009; 20(2):152–7.